GeneTex
United States (US)

EGFR antibody [F4]

Cat No. GTX10415

Host Mouse
Clonality Monoclonal
Clone Name F4
Isotype IgG1
Application WB, IHC-P, IP, ELISA
Reactivity Human
APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Dilution
WB 1:2,000
IHC-P Assay dependent
IP Assay dependent
ELISA Assay dependent
Not tested in other applications.

Calculated MW

134 kDa. ( Note )

Specificity/Sensitivity

This antibody recognizes specifically an intracellular domain of the EGF receptor.
PROPERTIES

Form

Liquid

Buffer

Ascites, 15 mM sodium azide

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Antigen Species

Human

Immunogen

synthetically produced residues 985-996 of the human EGF receptor.

Purification

Unpurified

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Epidermal Growth Factor Receptor,Erbb,Erbb1,Her1,Nisbd2,Pig61,Mena,Egfr

Background

The receptor for Epidermal Growth Factor is an integral cell membrane protein of 170 kD, which spans the membranes of a wide range of normal and malignant epithelial cells. It is a tyrosine-specific protein kinase with the capacity to phosphorylate tyrosine residues located near its carboxy-terminus. EGF-R has anextracellular region which binds EGF and consequently mediates the initial response of cells to EGF and an intra-cellular region which posseses the tyrosine kinase activity. As a result of EGF binding to its specific receptor, there is increased DNA synthesis as well as other events including cell proliferation, differentiation and repair of damaged epithelial tissue. The EGF-R has a half-life of approximately 10 hours in human fibroblasts, but in the presence of EGF this value is reduced to about 1 hour. A close similarity has been found between the sequence of the v-erb-B oncogene and the cytoplasmic and transmembrane part of the EGF-R (truncatedEGF-R). It is hypothesized that an inappropriate activation of the human erb-B gene either by truncation or overexpression plays a role in the development of the malignancy. This hypothesis is supported by studies, which have shown an increased number of EGF-R in various malignant tumors. High levels of EGF-R have been identified in sarcomas, gliomas, gynecological, breast, bladder, and lung tumors.

Database

Research Area

Package List Price ($)
$ 319